Just a few short months after getting off a $106 million funding round and beefing up its C-suite as it looks to tap its SNAP platform to fight resistance to cancer drugs, Tyra Biosciences has filed to raise $100 million in an IPO.
Tyra is taking aim at acquired resistance, a problem that makes targeted cancer treatments stop working. Over time, tumors with mutations such as EGFR rewire themselves to find a way around targeted therapies and continue to grow without relying on proteins made by the mutated gene.
